Related Experiment Video
Updated: Jun 20, 2026
The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
Published on: November 1, 2015
Efficacy of belimumab in children with systemic lupus erythematosus
Ying Yang1, Tianji Gao1, Shaonan Xu2
1Department of Rheumatology and Immunology, Baoding Hospital of Beijing Children's Hospital Capital Medical University, Baoding City, China.
Insights
Belimumab combined with standard therapy may help reduce glucocorticoid use in children with systemic lupus erythematosus (SLE). Further research is needed to confirm the efficacy and safety of this treatment approach.
Area of Science:
- Pediatric Rheumatology
- Immunology
- Pharmacology
Background:
- Systemic lupus erythematosus (SLE) is a chronic autoimmune disease affecting multiple organ systems.
- Pediatric SLE presents unique challenges in management, often requiring long-term immunosuppression.
- Belimumab, a biologic agent targeting B-cell activating factor, has shown promise in adult SLE but its role in pediatric SLE requires further investigation.
Purpose of the Study:
- To evaluate the efficacy and safety of belimumab in combination with standard therapy for pediatric patients with active SLE.
- To assess the potential glucocorticoid-sparing effect of belimumab in this population.
- To compare clinical and laboratory outcomes between patients receiving belimumab plus standard therapy and those receiving standard therapy alone.
Main Methods:
- A single-center retrospective observational cohort study included 40 children with active SLE.
- Patients were divided into two groups: belimumab plus standard therapy (n=20) and standard therapy alone (n=20).
- Belimumab was administered intravenously, and outcomes including clinical manifestations, laboratory parameters, SLEDAI-2000 scores, and glucocorticoid doses were assessed at 6 and 12 months.
Main Results:
- At 6 months, renal and mucocutaneous remission rates were comparable between groups, with slight numerical advantages in the belimumab group.
- Oral glucocorticoid doses decreased significantly more in the belimumab group compared to the standard therapy group (P < 0.05).
- While C3, C4, and SLEDAI-2000 scores improved in both groups, most other clinical and serological outcomes did not differ significantly. One patient in the belimumab group experienced reversible B-cell count reduction without severe adverse events.
Conclusions:
- Belimumab in combination with standard therapy demonstrated a potential glucocorticoid-sparing effect in children with SLE.
- The study suggests belimumab may be a valuable addition to the treatment regimen for pediatric SLE.
- Larger prospective studies are warranted to definitively establish the efficacy and safety profile of belimumab in pediatric SLE management.
Objective:
To evaluate the efficacy and safety of belimumab combined with standard therapy in children with systemic lupus erythematosus (SLE) in a single-center retrospective observational cohort.
Methods:
A total of 60 children with active SLE were screened, and 40 eligible patients were included. Patients were classified into a belimumab plus standard therapy group (n = 20) and a standard therapy alone group (n = 20). Belimumab was administered intravenously at 10 mg/kg every 2 weeks for the first three doses and every 4 weeks thereafter. Clinical manifestations, laboratory parameters, SLEDAI-2000 scores, glucocorticoid doses, and adverse events were compared between groups. The 6-month assessment was considered the primary observation time point, while 12-month outcomes were exploratory.
Results:
At 6 months, renal and mucocutaneous remission rates were 83% (15/18) and 94% (15/16) in the belimumab group, compared with 78% (7/9) and 85% (11/13) in the control group. At 12 months, the corresponding rates were 94% (15/16) and 94% (15/16) in the belimumab group, and 89% (8/9) and 85% (11/13) in the control group. C3, C4, and SLEDAI-2000 scores improved significantly in both groups. Most clinical and serological outcomes did not differ significantly between groups. Oral glucocorticoid doses decreased more markedly in the belimumab group than in the control group (53.55 ± 8.43 to 6.72 ± 3.50 mg/day vs. 55.50 ± 6.05 to 14.81 ± 5.54 mg/day; P < 0.05). One patient experienced reversible reductions in IgG levels and B-cell counts, with no severe infections or infusion reactions.
Conclusions:
Belimumab plus standard therapy showed a potential glucocorticoid-sparing effect in pediatric SLE, but larger prospective studies are needed to confirm its efficacy and safety.
